Precision Medicine Care (PMC)
Medicine Care (PMC™), former PMCDx, announced that the American Medical Association (AMA) has voted to approve new Proprietary Laboratory Analyses (PLA) code for the company’s RenaDx™ comprehensive kidney genetic testing panel, marking a major milestone for the company and the renal genetics field.
The company’s RenaDx™ and RenaXome™ platforms deliver comprehensive nephrogenomic insights, empowering clinicians with actionable data
🔬 Driving Innovation in Maryland: PMCDx at the Germantown Innovation Center
Community Connect: Code to Cure highlighted how AI is transforming life sciences today—accelerating discovery, reshaping patient care, and opening early opportunities for those ready to lead the next wave of innovation.
We are thrilled to share an illuminating discussion with our CEO, Sherry Dadgar, Ph.D, FACMG, NYCQ, and County Executive Marc Elrich, diving into the transformative world of Precision Medicine.
Meet Sherry Dadgar, Ph.D., CEO and laboratory technical director for PMCDx. Dr. Dadgar discusses how her company helps improve health care for each individual based on their cellular and molecular fingerprints and why PMCDx chose to locate in MoCo.